Relief Therapeutics Holding AG (RLFTF)

[ratna1]

Good Evening Kiwi & All! Since I have not been online for a while I don't know if this has been posted before, but I wonder what is your assessment of PHAS giving up on its VIP clinical study due to a lack of significant statistical benefits:

PhaseBio pulls the plug on pemziviptadil COVID-19 study
Oct. 23, 2020 9:15 AM ET|About: PhaseBio Pharmaceuticals,...
By: Vandana Singh, SA News Editor
PhaseBio Pharmaceuticals (NASDAQ:PHAS) slips 5% in premarket on light volume, after it announced to discontinue VANGARD trial evaluating pemziviptadil (PB1046) as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome.

Based on feedback from the FDA, the company determined that the 70 patients targeted for enrollment in each of the VANGARD trial’s treatment arms would be insufficient in size to adequately evaluate mortality and that at least one additional clinical trial with a mortality endpoint, would be required.

After an interim analysis of the first 25 patients, PhaseBio did not observe any data trends in the 40 mg or 100 mg pemziviptadil-treated arms suggesting a reasonable probability of achieving the primary efficacy endpoint. Pemziviptadil was generally well tolerated, and no safety concerns were identified.